| __timestamp | MiMedx Group, Inc. | Telix Pharmaceuticals Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 12665000 | 22622695 |
| Thursday, January 1, 2015 | 20202000 | 24863028 |
| Friday, January 1, 2016 | 32407000 | 21351001 |
| Sunday, January 1, 2017 | 35219000 | 53837297 |
| Monday, January 1, 2018 | 36386000 | 16080096 |
| Tuesday, January 1, 2019 | 43081000 | 18525736 |
| Wednesday, January 1, 2020 | 39330000 | 2024000 |
| Friday, January 1, 2021 | 43283000 | 2548000 |
| Saturday, January 1, 2022 | 48316000 | 61556000 |
| Sunday, January 1, 2023 | 54634000 | 188157000 |
Unleashing the power of data
In the ever-evolving landscape of pharmaceuticals, understanding cost dynamics is crucial. This chart offers a fascinating glimpse into the cost of revenue trends for Telix Pharmaceuticals Limited and MiMedx Group, Inc. over the past decade.
From 2014 to 2023, MiMedx Group, Inc. saw a steady increase in its cost of revenue, peaking at approximately 54.6 million in 2023, a remarkable 331% increase from 2014. In contrast, Telix Pharmaceuticals Limited experienced more volatility. After a dip in 2020, their costs surged by over 900% to reach nearly 188 million in 2023.
These trends highlight the differing strategies and market conditions faced by these companies. While MiMedx's steady growth suggests a consistent expansion strategy, Telix's fluctuations may indicate strategic pivots or market challenges. Understanding these patterns can provide valuable insights for investors and industry analysts alike.
Cost of Revenue Trends: Novo Nordisk A/S vs MiMedx Group, Inc.
Cost Insights: Breaking Down Regeneron Pharmaceuticals, Inc. and Telix Pharmaceuticals Limited's Expenses
Cost of Revenue Comparison: Takeda Pharmaceutical Company Limited vs Telix Pharmaceuticals Limited
Cost Insights: Breaking Down Incyte Corporation and Telix Pharmaceuticals Limited's Expenses
Analyzing Cost of Revenue: Dr. Reddy's Laboratories Limited and MiMedx Group, Inc.
Analyzing Cost of Revenue: Pharming Group N.V. and Telix Pharmaceuticals Limited
Cost of Revenue: Key Insights for Telix Pharmaceuticals Limited and Alkermes plc
Cost Insights: Breaking Down Telix Pharmaceuticals Limited and Perrigo Company plc's Expenses
Cost Insights: Breaking Down Ligand Pharmaceuticals Incorporated and MiMedx Group, Inc.'s Expenses
Cost of Revenue Comparison: Wave Life Sciences Ltd. vs MiMedx Group, Inc.
Comparing Cost of Revenue Efficiency: Celldex Therapeutics, Inc. vs MiMedx Group, Inc.
Xencor, Inc. vs MiMedx Group, Inc.: Efficiency in Cost of Revenue Explored